Tarsus Pharmaceuticals (TARS) Cost of Revenue (2021 - 2026)

Tarsus Pharmaceuticals' Cost of Revenue history runs 6 years deep, the most recent figure standing at $9.4 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 80.31% year-over-year to $9.4 million; the TTM figure through Mar 2026 stood at $34.9 million (up 112.84% YoY), while the FY2025 annual figure was $30.7 million, up 139.23% from the prior year.
• Cost of Revenue for Q1 2026 stood at $9.4 million, down from $10.9 million in the prior quarter.
• The five-year high for Cost of Revenue was $10.9 million in Q4 2025, with the low at $33000.0 in Q1 2022.
• The 5-year median for Cost of Revenue is $3.1 million (2024), against an average of $4.0 million.
• Peak annual rise in Cost of Revenue reached 1766.67% in 2022, while the deepest fall reached 97.46% in 2022.
• Tarsus Pharmaceuticals' Cost of Revenue stood at $400000.0 in 2022, then jumped by 204.0% to $1.2 million in 2023, then jumped by 305.1% to $4.9 million in 2024, then surged by 121.82% to $10.9 million in 2025, then fell by 14.01% to $9.4 million in 2026.
• Business Quant data shows TARS's Cost of Revenue at $9.4 million in Q1 2026, $10.9 million in Q4 2025, and $8.3 million in Q3 2025.